Bruce C Baguley

List of Publications by Year
in descending order

263 papers	12,890 citations	23567 58 h-index	32842 100 g-index
268 all docs	268 docs citations	268 times ranked	12970 citing authors

#	Article	IF	Citations
1	Genomic and signalling pathway characterization of the NZM panel of melanoma cell lines: A valuable model for studying the impact of genetic diversity in melanoma. Pigment Cell and Melanoma Research, 2021, 34, 136-143.	3.3	9
2	DNA-Binding Anticancer Drugs: One Target, Two Actions. Molecules, 2021, 26, 552.	3.8	23
3	Genome-wide DNA methylation and RNA expression differences correlate with invasiveness in melanoma cell lines. Epigenomics, 2021, 13, 577-598.	2.1	6
4	SOX2OT Long Noncoding RNA Is Regulated by the UPR in Oestrogen Receptor-Positive Breast Cancer. Sci, 2021, 3, 26.	3.0	2
5	Validating TDP1 as an Inhibition Target for the Development of Chemosensitizers for Camptothecin-Based Chemotherapy Drugs. Oncology and Therapy, 2021, 9, 541-556.	2.6	11
6	Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer. BMC Cancer, 2020, 20, 470.	2.6	21
7	AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. Journal of Thoracic Oncology, 2020, 15, 973-999.	1.1	66
8	SOX2OT Long Noncoding RNA Is Regulated by the UPR in Oestrogen Receptor-Positive Breast Cancer. Sci, 2020, 2, 24.	3.0	1
9	Synthesis and biological evaluation of solubilized sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474. Bioorganic and Medicinal Chemistry, 2019, 27, 1529-1545.	3.0	12
10	Multiseed liposomal drug delivery system using micelle gradient as driving force to improve amphiphilic drug retention and its anti-tumor efficacy. Drug Delivery, 2018, 25, 611-622.	5.7	14
11	Derivation of Breast Cancer Cell Lines Under Physiological (5%) Oxygen Concentrations. Frontiers in Oncology, 2018, 8, 425.	2.8	16
12	PIK3CAâ€mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation. Pigment Cell and Melanoma Research, 2017, 30, 353-367.	3.3	9
13	Novel pyrazolo[1,5- a]pyridines with improved aqueous solubility as p110Î±-selective PI3 kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 187-190.	2.2	9
14	Synthesis and biological evaluation of sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474. Bioorganic and Medicinal Chemistry, 2017, 25, 5859-5874.	3.0	14
15	Multiple Isoforms of ANRIL in Melanoma Cells: Structural Complexity Suggests Variations in Processing. International Journal of Molecular Sciences, 2017, 18, 1378.	4.1	45
16	Endocrine Therapy of Estrogen Receptor-Positive Breast Cancer Cells: Early Differential Effects on Stem Cell Markers. Frontiers in Oncology, 2017, 7, 184.	2.8	32
17	The Genes of Life and Death: A Potential Role for Placentalâ€Specific Genes in Cancer. BioEssays, 2017, 39, 1700091.	2.5	13
18	Signaling Pathways in Melanogenesis. International Journal of Molecular Sciences, 2016, 17, 1144.	4.1	605

#	Article	IF	Citations
19	Improving drug retention in liposomes by aging with the aid of glucose. International Journal of Pharmaceutics, 2016, 505, 194-203.	5.2	9
20	Differences in the carcinogenic evaluation of glyphosate between the International Agency for Research on Cancer (IARC) and the European Food Safety Authority (EFSA). Journal of Epidemiology and Community Health, 2016, 70, 741-745.	3.7	138
21	Selected GRIN2A mutations in melanoma cause oncogenic effects that can be modulated by extracellular glutamate. Cell Calcium, 2016, 60, 384-395.	2.4	11
22	Optimization of the formation of embedded multicellular spheroids of MCF-7 cells: How to reliably produce a biomimetic 3D model. Analytical Biochemistry, 2016, 515, 47-54.	2.4	54
23	Evidence that phospholipase C is involved in the antitumour action of NSC768313, a new thieno[2,3-b]pyridine derivative. Cancer Cell International, 2016, 16, 18.	4.1	27
24	The Regulatory Role of Long Noncoding RNAs in Cancer Drug Resistance. Methods in Molecular Biology, 2016, 1395, 207-227.	0.9	20
25	Classical and Targeted Anticancer Drugs: An Appraisal of Mechanisms of Multidrug Resistance. Methods in Molecular Biology, 2016, 1395, 19-37.	0.9	11
26	Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth. Frontiers in Oncology, 2015, 5, 135.	2.8	52
27	Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines. PLoS ONE, 2015, 10, e0131400.	2.5	43
28	Epigenetic regulation in human melanoma: past and future. Epigenetics, 2015, 10, 103-121.	2.7	237
29	Post-insertion of poloxamer 188 strengthened liposomal membrane and reduced drug irritancy and in vivo precipitation, superior to PEGylation. Journal of Controlled Release, 2015, 203, 161-169.	9.9	42
30	Exploring the isoform selectivity of TGX-221 related pyrido[1,2-a]pyrimidinone-based Class IA PI 3-kinase inhibitors: Synthesis, biological evaluation and molecular modelling. Bioorganic and Medicinal Chemistry, 2015, 23, 3796-3808.	3.0	9
31	Strategies to Maximize Liposomal Drug Loading for a Poorly Water-soluble Anticancer Drug. Pharmaceutical Research, 2015, 32, 1451-1461.	3.5	49
32	Relationships between Signaling Pathway Usage and Sensitivity to a Pathway Inhibitor: Examination of Trametinib Responses in Cultured Breast Cancer Lines. PLoS ONE, 2014, 9, e105792.	2.5	23
33	Therapeutic targeting of tumor angiogenesis: how far have we come?. Clinical Investigation, 2014, 4, 1113-1122.	0.0	0
34	Preliminary Evidence That High-Dose Vitamin C has a Vascular Disrupting Action in Mice. Frontiers in Oncology, 2014, 4, 310.	2.8	5
35	Evidence for the Existence of Triple-Negative Variants in the MCF-7 Breast Cancer Cell Population. BioMed Research International, 2014, 2014, 1-7.	1.9	40
36	Mutation-Specific RAS Oncogenicity Explains NRAS Codon 61 Selection in Melanoma. Cancer Discovery, 2014, 4, 1418-1429.	9.4	174

#	Article	IF	Citations
37	Evidence That GRIN2A Mutations in Melanoma Correlate with Decreased Survival. Frontiers in Oncology, 2014, 3, 333.	2.8	16
38	Hormone Resistance in Two MCF-7 Breast Cancer Cell Lines is Associated with Reduced mTOR Signaling, Decreased Glycolysis, and Increased Sensitivity to Cytotoxic Drugs. Frontiers in Oncology, 2014, 4, 221.	2.8	23
39	Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent. Cancer Chemotherapy and Pharmacology, 2014, 74, 25-35.	2.3	8
40	Novel pyrazolo[1,5-a]pyridines as PI3K inhibitors: variation of the central linker group. MedChemComm, 2014, 5, 41-46.	3.4	12
41	Physicochemical characterization of asulacrine towards the development of an anticancer liposomal formulation via active drug loading: Stability, solubility, lipophilicity and ionization. International Journal of Pharmaceutics, 2014, 473, 528-535.	5.2	17
42	Keeping abreast with long non-coding RNAs in mammary gland development and breast cancer. Frontiers in Genetics, 2014, 5, 379.	2.3	76
43	Retrotransposon Hypomethylation in Melanoma and Expression of a Placenta-Specific Gene. PLoS ONE, 2014, 9, e95840.	2.5	11
44	Emerging Role of Long Non-Coding RNA SOX2OT in SOX2 Regulation in Breast Cancer. PLoS ONE, 2014, 9, e102140.	2.5	119
45	Tumour tissue selectivity in the uptake and retention of SN 28049, a new topoisomerase II-directed anticancer agent. Cancer Chemotherapy and Pharmacology, 2013, 72, 1013-1022.	2.3	4
46	Synthesis and biological evaluation of novel phosphatidylinositol 3-kinase inhibitors: Solubilized 4-substituted benzimidazole analogs of 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474). European Journal of Medicinal Chemistry, 2013, 64, 137-147.	5.5	17
47	MITF and PAX3 Play Distinct Roles in Melanoma Cell Migration; Outline of a â€œGenetic Switchâ€•Theory Involving MITF and PAX3 in Proliferative and Invasive Phenotypes of Melanoma. Frontiers in Oncology, 2013, 3, 229.	2.8	27
48	The Role of the Hippo Pathway in Melanocytes and Melanoma. Frontiers in Oncology, 2013, 3, 123.	2.8	26
49	Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors. Frontiers in Genetics, 2013, 4, 66.	2.3	40
50	Variable Expression of GLIPR1 Correlates with Invasive Potential in Melanoma Cells. Frontiers in Oncology, 2013, 3, 225.	2.8	25
51	Therapeutic reactivation of mutant p53 protein by quinazoline derivatives. Investigational New Drugs, 2012, 30, 2035-2045.	2.6	9
52	Identification of cyclohexanone derivatives that act as catalytic inhibitors of topoisomerase I: effects on tamoxifen-resistant MCF-7 cancer cells. Investigational New Drugs, 2012, 30, 2103-2112.	2.6	11
53	Anticancer potential of tumor vascular disrupting agents: review of the latest clinical evidence. Clinical Investigation, 2012, 2, 985-993.	0.0	11
54	Mathematical Determination of Cell Population Doubling Times for Multiple Cell Lines. Bulletin of Mathematical Biology, 2012, 74, 2510-2534.	1.9	11

#	Article	IF	Citations
55	Comparison of a homologous series of benzonaphthyridine anti-cancer agents in mice: divergence between tumour and plasma pharmacokinetics. Cancer Chemotherapy and Pharmacology, 2012, 70, 151-160.	2.3	8
56	Discovery of pyrazolo[1,5-a]pyridines as p110Î±-selective PI3 kinase inhibitors. Bioorganic and Medicinal Chemistry, 2012, 20, 69-85.	3.0	30
57	Novel pyrazolo[1,5-a]pyridines as p110Î±-selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SAR. Bioorganic and Medicinal Chemistry, 2012, 20, 58-68.	3.0	34
58	A rapid LCâ€"MS/MS method for the quantitation of a series of benzonaphthyridine derivatives: Application to in vivo pharmacokinetic and lipophilicity studies in drug development. Journal of Pharmaceutical and Biomedical Analysis, 2012, 63, 9-16.	2.8	7
59	Centrosomal dysregulation in human metastatic melanoma cell lines. Cancer Genetics, 2011, 204, 477-485.	0.4	14
60	The paradox of cancer cell apoptosis. Frontiers in Bioscience - Landmark, 2011, 16, 1759.	3.0	9
61	PAX3 knockdown in metastatic melanoma cell lines does not reduce MITF expression. Melanoma Research, 2011, 21, 24-34.	1.2	17
62	Synthesis and Biological Evaluation of Novel Analogues of the Pan Class I Phosphatidylinositol 3-Kinase (PI3K) Inhibitor 2-(Difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474). Journal of Medicinal Chemistry, 2011, 54, 7105-7126.	6.4	97
63	Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide. Investigational New Drugs, 2011, 29, 1102-1110.	2.6	12
64	In vivo and in vitro assessment of the action of SN 28049, a benzonaphthyridine derivative targeting topoisomerase II, on the murine Colon 38 carcinoma. Investigational New Drugs, 2011, 29, 1504-1510.	2.6	5
65	Preclinical Efficacy of Vascular Disrupting Agents in Nonâ€"Small-Cell Lung Cancer. Clinical Lung Cancer, 2011, 12, 81-86.	2.6	14
66	Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells. Cancer Biology and Therapy, 2011, 11, 938-946.	3.4	74
67	The CDKN2A G500 Allele Is More Frequent in GBM Patients with No Defined Telomere Maintenance Mechanism Tumors and Is Associated with Poorer Survival. PLoS ONE, 2011, 6, e26737.	2.5	27
68	Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice. Cancer Chemotherapy and Pharmacology, 2010, 65, 1145-1152.	2.3	10
69	Multiple Drug Resistance Mechanisms in Cancer. Molecular Biotechnology, 2010, 46, 308-316.	2.4	426
70	Disrupting established tumor blood vessels. Cancer, 2010, 116, 1859-1871.	4.1	138
71	Temporal aspects of the action of ASA404 (vadimezan; DMXAA). Expert Opinion on Investigational Drugs, 2010, 19, 1413-1425.	4.1	39
72	MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivity. Cancer Biology and Therapy, 2010, 9, 717-724.	3.4	54

#	Article	IF	Citations
73	ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy. Future Oncology, 2010, 6, 1537-1543.	2.4	16
74	The ubiquitinâ€"proteasome system is inhibited by p53 protein expression in human ovarian cancer cells. Cancer Letters, 2010, 294, 82-90.	7.2	3
75	Pharmacokinetics and pharmacodynamics of chlorambucil delivered in long-circulating nanoemulsion. Journal of Drug Targeting, 2010, 18, 125-133.	4.4	46
76	Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA;) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.6	10
77	Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. International Journal of Pharmaceutics, 2009, 367, 179-186.	5.2	100
78	Using a stem cell and progeny model to illustrate the relationship between cell cycle times of in vivo human tumour cell tissue populations, in vitro primary cultures and the cell lines derived from them. Journal of Theoretical Biology, 2009, 260, 563-571.	1.7	9
79	A Gene Expression Signature of Invasive Potential in Metastatic Melanoma Cells. PLoS ONE, 2009, 4, e8461.	2.5	74
80	Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide. Cancer Chemotherapy and Pharmacology, 2008, 61, 497-502.	2.3	14
81	The role of topoisomerases and RNA transcription in the action of the antitumour benzonaphthyridine derivative SN 28049. Cancer Chemotherapy and Pharmacology, 2008, 62, 753-762.	2.3	13
82	Development and validation of a liquid chromatographyâ€"mass spectrometry (LCâ€"MS) assay for the determination of the anti-cancer agent N-[2-(dimethylamino)ethyl]-2,6-dimethyl-1-oxo-1,2-dihydrobenzo[b]-1,6-naphthyridine-4-carboxamide (SN) Tj ETQq0 0 0 rgBT /Overlock 2008, 875, 368-372.	2.8	8
83	Development and validation of bioanalytical method for the determination of asulacrine in plasma by liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis, 2008, 46, 386-390.	2.8	5
84	In vitro antitumour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake. Journal of Inorganic Biochemistry, 2008, 102, 303-310.	3.5	174
85	Pharmacokinetics and pharmacodynamics of chlorambucil delivered in parenteral emulsion. International Journal of Pharmaceutics, 2008, 360, 115-121.	5.2	65
86	Population Pharmacokinetic-Pharmacodynamic Model of the Vascular-Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid in Cancer Patients. Clinical Cancer Research, 2008, 14, 2102-2110.	7.0	20
87	The use of human tumour cell lines in the discovery of new cancer chemotherapeutic drugs. Expert Opinion on Drug Discovery, 2008, 3, 153-161.	5.0	6
88	Synthesis, biological evaluation and molecular modelling of sulfonohydrazides as selective PI3K p110Î± inhibitors. Bioorganic and Medicinal Chemistry, 2007, 15, 7677-7687.	3.0	51
89	Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours. Cancer Chemotherapy and Pharmacology, 2007, 59, 661-669.	2.3	20
90	Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Investigational New Drugs, 2007, 25, 271-276.	2.6	15

#	Article	IF	Citations
91	NF-kappaB-independent induction of endothelial cell apoptosis by the vascular disrupting agent DMXAA. Anticancer Research, 2007, 27, 327-34.	1.1	10
92	Tumor Stem Cell Niches: A New Functional Framework for the Action of Anticancer Drugs. Recent Patents on Anti-Cancer Drug Discovery, 2006, 1, 121-127.	1.6	29
93	Phenazine-1-carboxamides: Structureâ€"cytotoxicity relationships for 9-substituents and changes in the H-bonding pattern of the cationic side chain. Bioorganic and Medicinal Chemistry, 2006, 14, 1160-1168.	3.0	18
94	Association of Mutant TP53 with Alternative Lengthening of Telomeres and Favorable Prognosis in Glioma. Cancer Research, 2006, 66, 6473-6476.	0.9	72
95	5,6-Dimethylxanthenone-4-Acetic Acid in the Treatment of Refractory Tumors: a Phase I Safety Study of a Vascular Disrupting Agent. Clinical Cancer Research, 2006, 12, 1776-1784.	7.0	90
96	Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridin-(5H)ones. Bioorganic and Medicinal Chemistry, 2005, 13, 1341-1355.	3.0	41
97	Synthesis and cytotoxic activity of N-[(alkylamino)alkyl]carboxamide derivatives of 7-oxo-7H-benz[de]anthracene, 7-oxo-7H-naphtho[1,2,3-de]quinoline, and 7-oxo-7H-benzo[e]perimidine. Bioorganic and Medicinal Chemistry, 2005, 13, 3657-3665.	3.0	21
98	Modelling the flow of cytometric data obtained from unperturbed human tumour cell lines: parameter fitting and comparison. Bulletin of Mathematical Biology, 2005, 67, 815-830.	1.9	35
99	Disrupting tumour blood vessels. Nature Reviews Cancer, 2005, 5, 423-435.	28.4	867
100	Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells. European Journal of Pharmaceutical Sciences, 2005, 24, 513-524.	4.0	29
101	Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability. International Journal of Cancer, 2005, 116, 322-326.	5.1	70
102	Do Negative Feedback Oscillations Drive Variations in the Length of the Tumor Cell Division Cycle?. Oncology Research, 2005, 15, 291-294.	1.5	3
103	A Comparison of the Ability of DMXAA and Xanthenone Analogues to Activate NF-Î°B in Murine and Human Cell Lines. Oncology Research, 2005, 15, 351-364.	1.5	10
104	Thalidomide Pharmacokinetics and Metabolite Formation in Mice, Rabbits, and Multiple Myeloma Patients. Clinical Cancer Research, 2004, 10, 5949-5956.	7.0	57
105	Metabolism of Thalidomide in Liver Microsomes of Mice, Rabbits, and Humans. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 571-577.	2.5	50
106	Modelling cell population growth with applications to cancer therapy in human tumour cell lines. Progress in Biophysics and Molecular Biology, 2004, 85, 353-368.	2.9	42
107	Induction of tumour necrosis factor and interferon-Î³ in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites. Biochemical Pharmacology, 2004, 67, 937-945.	4.4	26
108	Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor. Cancer Chemotherapy and Pharmacology, 2004, 53, 377-383.	2.3	13

#	Article	IF	Citations
109	Modelling cell death in human tumour cell lines exposed to the anticancer drug paclitaxel. Journal of Mathematical Biology, 2004, 49, 329-357.	1.9	55
110	Determination of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide in Caco-2 monolayers by liquid chromatography with fluorescence detection: application to transport studies. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 809, 87-97.	2.3	10
111	A mathematical model for analysis of the cell cycle in cell lines derived from human tumors. Journal of Mathematical Biology, 2003, 47, 295-312.	1.9	100
112	Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. Biochemical Pharmacology, 2003, 65, 109-120.	4.4	12
113	Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. Biochemical Pharmacology, 2003, 65, 1853-1865.	4.4	6
114	Synthesis and Cytotoxic Activity of Carboxamide Derivatives of Benzo[b][1,6]naphthyridines. Journal of Medicinal Chemistry, 2003, 46, 1049-1054.	6.4	51
115	Antivascular therapy of cancer: DMXAA. Lancet Oncology, The, 2003, 4, 141-148.	10.7	167
116	Dual Topoisomerase I / II Inhibitors in Cancer Therapy. Current Topics in Medicinal Chemistry, 2003, 3, 339-353.	2.1	136
117	Estimation of Radiation-Induced Interphase Cell Death in Cultures of Human Tumor Material and in Cell Lines. Oncology Research, 2003, 14, 297-304.	1.5	14
118	Mechanisms of Action of DNA Intercalating Acridine-based Drugs: How Important are Contributions from Electron Transfer and Oxidative Stress?. Current Medicinal Chemistry, 2003, 10, 2643-2649.	2.4	65
119	Thalidomide metabolites in mice and patients with multiple myeloma. Clinical Cancer Research, 2003, 9, 1680-8.	7.0	32
120	Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling. Clinical Cancer Research, 2003, 9, 6545-50.	7.0	12
121	Cultures of Surgical Material from Lung Cancers: A Kinetic Approach. , 2003, 74, 527-544.		1
122	In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II. Anti-Cancer Drugs, 2002, 13, 15-28.	1.4	61
123	Potential of DMXAA combination therapy for solid tumors. Expert Review of Anticancer Therapy, 2002, 2, 593-603.	2.4	27
124	Novel Strategies for Overcoming Multidrug Resistance in Cancer. BioDrugs, 2002, 16, 97-103.	4.6	11
125	Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice. Cancer Chemotherapy and Pharmacology, 2002, 49, 20-26.	2.3	14
126	Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide. Cancer Chemotherapy and Pharmacology, 2002, 50, 186-192.	2.3	19

#	Article	IF	Citations
127	Synthesis and cytotoxic activity of N -(2-Diethylamino)ethylcarboxamide and other derivatives of 10 H -Quindoline. Bioorganic and Medicinal Chemistry, 2002, 10, 2381-2386.	3.0	22
128	5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. Investigational New Drugs, 2002, 20, 281-295.	2.6	42
129	Synthesis and Cytotoxic Activity of 7-Oxo-7H-dibenz[f,ij]isoquinoline and 7-Oxo-7H-benzo[e]perimidine Derivatives. Journal of Medicinal Chemistry, 2001, 44, 2004-2014.	6.4	86
130	Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents. Clinica Chimica Acta, 2001, 314, 159-166.	1.1	33
131	Dicationic Bis(9-methylphenazine-1-carboxamides):Â Relationships between Biological Activity and Linker Chain Structure for a Series of Potent Topoisomerase Targeted Anticancer Drugs. Journal of Medicinal Chemistry, 2001, 44, 1407-1415.	6.4	62
132	Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anti-Cancer Drugs, 2001, 12, 359-367.	1.4	50
133	Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemotherapy and Pharmacology, 2001, 47, 491-497.	2.3	18
134	Positioning of the Carboxamide Side Chain in 11-Oxo-11 H -indeno[1,2- b]quinolinecarboxamide Anticancer Agents: Effects on Cytotoxicity. Bioorganic and Medicinal Chemistry, 2001, 9, 445-452.	3.0	54
135	Synthesis and antitumor activity of some indeno[1,2- b]quinoline-based bis carboxamides. Bioorganic and Medicinal Chemistry, 2000, 8, 977-984.	3.0	87
136	Synthesis of Substituted Indeno[1,2-b]quinoline-6-carboxamides, [1]benzothieno[3,2-b]quinoline-4-carboxamides and 10H-quindoline-4-carboxamides: Evaluation of Structureâ€"Activity Relationships for Cytotoxicity. Bioorganic and Medicinal Chemistry, 2000, 8, 2461-2466.	3.0	37
137	Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide. Cancer Chemotherapy and Pharmacology, 2000, 46, 135-141.	2.3	30
138	Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes. Cancer Chemotherapy and Pharmacology, 2000, 46, 343-350.	2.3	197
139	Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs. Cancer Chemotherapy and Pharmacology, 2000, 45, 417-422.	2.3	48
140	Inhibition of Tumor Blood Flow. , 2000, 25, 133-157.		1
141	Bis(phenazine-1-carboxamides):Â Structureâ"Activity Relationships for a New Class of Dual Topoisomerase I/II-Directed Anticancer Drugs. Journal of Medicinal Chemistry, 2000, 43, 1350-1358.	6.4	95
142	Ring-substituted 11-oxo-11 H -indeno[1,2- b]quinoline-6-carboxamides with similar patterns of cytotoxicity to the dual topo I/II inhibitor DACA. Bioorganic and Medicinal Chemistry, 1999, 7, 2801-2809.	3.0	43
143	Mechanism of cytotoxicity of N -[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II. Cancer Chemotherapy and Pharmacology, 1999, 43, 302-308.	2.3	27
144	Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit. Cancer Chemotherapy and Pharmacology, 1999, 43, 323-330.	2.3	40

#	Article	IF	Citations
145	Phase I study of the cytotoxic agent N â€Š-[2-(dimethylamino)ethyl]acridine-4-carboxamide. Cancer Chemotherapy and Pharmacology, 1999, 44, 39-44.	2.3	45
146	Plasma pharmacokinetics of Nâ€Š -[2-(dimethylamino)ethyl]acridine-4-carboxamide in a phase I trial. Cancer Chemotherapy and Pharmacology, 1999, 44, 45-50.	2.3	22
147	Metabolism of N ?-[2-(dimethylamino)ethyl]acridine-4-carboxamide in cancer patients undergoing a phase I clinical trial. Cancer Chemotherapy and Pharmacology, 1999, 44, 51-58.	2.3	28
148	Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases Ill± and Î². Cancer Chemotherapy and Pharmacology, 1999, 44, 275-282.	2.3	15
149	Structureâ^'Activity Relationships for Substituted Bis(acridine-4-carboxamides):â€‰ A New Class of Anticancer Agents. Journal of Medicinal Chemistry, 1999, 42, 2383-2393.	6.4	145
150	Early stages of the apoptotic pathway in plant cells are reversible. Plant Journal, 1998, 13, 803-814.	5.7	115
151	Major Changes in Chromatin Condensation Suggest the Presence of an Apoptotic Pathway in Plant Cells. Experimental Cell Research, 1998, 241, 46-54.	2.6	39
152	Structureâ^'Activity Relationships for Acridine-Substituted Analogues of the Mixed Topoisomerase I/II Inhibitor N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide. Journal of Medicinal Chemistry, 1997, 40, 1919-1929.	6.4	70
153	Synthesis and Antitumor Properties ofN-[2-(Dimethylamino)ethyl]carboxamide Derivatives of Fused Tetracyclic Quinolines and Quinoxalines:Â A New Class of Putative Topoisomerase Inhibitors. Journal of Medicinal Chemistry, 1997, 40, 2040-2046.	6.4	112
154	Selective antitumour activity of metal complexes of bidentate pyridylphosphines. Journal of Inorganic Biochemistry, 1997, 67, 154.	3.5	8
155	Sequence-specific interactions of minor groove binders with the 154 base pair hindlll-rsal restriction fragment of cDNA of the human tau 40 protein involved in pathology of alzheimer's disease. IUBMB Life, 1997, 41, 143-152.	3.4	0
156	The potential of N -[2-(dimethylamino)ethyl]acridine-4-carboxamide]to circumvent three multidrug-resistance phenotypes in vitro. Cancer Chemotherapy and Pharmacology, 1997, 39, 424-430.	2.3	29
157	Carbon-11 labelling of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and determination of plasma metabolites in man. Applied Radiation and Isotopes, 1997, 48, 487-492.	1.5	9
158	In vivo effects of chlorophyllin on the antitumour agent cyclophosphamide. , 1997, 70, 84-89.		19
159	Determination of the activation spectrum of aluminium phthalocyanine chloride against cultured meningioma cells using a tunable laser. Journal of Clinical Neuroscience, 1996, 3, 252-256.	1.5	5
160	Application of fluorescence in situ hybridisation to study the relationship between cytotoxicity, chromosome aberrations, and changes in chromosome number after treatment with the topoisomerase II inhibitor amsacrine. Environmental and Molecular Mutagenesis, 1996, 27, 255-262.	2.2	17
161	Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, 1994: PHARMACOKINETIC/CYTOKINETIC PRINCIPLES IN THE CHEMOTHERAPY OF SOLID TUMOURS. Clinical and Experimental Pharmacology and Physiology, 1995, 22, 825-828.	1.9	12
162	Synthesis, DNA interactions and biological activity of DNA minor groove targeted polybenzamide-linked nitrogen mustards. Bioorganic and Medicinal Chemistry, 1995, 3, 679-691.	3.0	24

#	Article	IF	Citations
163	Induction of tumour necrosis factor-? by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemotherapy and Pharmacology, 1995, 36, 143-148.	2.3	113
164	The morphological effects of the antiâ€"tumor agents flavone acetic acid and 5,6â€"dimethyl xanthenone acetic acid on the colon 38 mouse tumor. Pathology, 1994, 26, 161-169.	0.6	19
165	Topoisomerase II enzymes and mutagenicity. Environmental and Molecular Mutagenesis, 1994, 24, 245-261.	2.2	90
166	DNA-Directed Alkylating Agents. 6. Synthesis and Antitumor Activity of DNA Minor Groove-Targeted Aniline Mustard Analogs of Pibenzimol (Hoechst 33258). Journal of Medicinal Chemistry, 1994, 37, 4338-4345.	6.4	141
167	Electron-Deficient DNA Intercalating Agents as Antitumor Drugs: Aza Analogs of the Experimental Clinical Agent N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide. Journal of Medicinal Chemistry, 1994, 37, 593-597.	6.4	28
168	Novel carbamate analogues of amsacrine with activity against non-cycling murine and human tumour cells. Cancer Chemotherapy and Pharmacology, 1994, 34, 159-165.	2.3	0
169	Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours. Cancer Chemotherapy and Pharmacology, 1994, 35, 153-160.	2.3	0
170	Proliferative assays for the assessment of radiosensitivity of tumor cell lines using 96-well microcultures. Radiation Oncology Investigations, 1993, 1, 261-269.	0.9	13
171	Cytokinetic differences in the action ofN-[2-(dimethylamino)ethyl]acridine-4-carboxamide as compared with that of amsacrine and doxorubicin. Cancer Chemotherapy and Pharmacology, 1993, 32, 463-470.	2.3	15
172	In vitro assessment ofN-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance. Cancer Chemotherapy and Pharmacology, 1993, 31, 401-406.	2.3	59
173	Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemotherapy and Pharmacology, 1993, 33, 77-81.	2.3	41
174	DNA Binding of the Nonintercalative Ligands SN-6132, SN-6131 and SN-6113: Minor Variations of the Ligand Structure May Cause Changes in the Base Pair Preference. Journal of Biomolecular Structure and Dynamics, 1992, 10, 551-564.	3.5	7
175	Potential antitumor agents. 64. Synthesis and antitumor evaluation of dibenzo[1,4]dioxin-1-carboxamides: a new class of weakly binding DNA-intercalating agents. Journal of Medicinal Chemistry, 1992, 35, 258-266.	6.4	34
176	DNA-directed alkylating agents. 5. Acridinecarboxamide derivatives of (1,2-diaminoethane)dichloroplatinum(II). Journal of Medicinal Chemistry, 1992, 35, 2983-2987.	6.4	62
177	Stimulation of macrophage tumouricidal activity by 5,6-dimethyl-xanthenone-4-acetic acid, a potent analogue of the antitumour agent flavone-8-acetic acid. Biochemical Pharmacology, 1992, 44, 192-195.	4.4	23
178	Modulation of superoxide production from murine macrophages by the antitumour agent flavone acetic acid and xanthenone acetic acid analogues. Biochemical Pharmacology, 1992, 43, 386-389.	4.4	6
179	Nitric oxide production in endotoxin-resistant C3H/HeJ mice stimulated with flavone-8-acetic acid and xanthenone-4-acetic acid analogues. Biochemical Pharmacology, 1992, 43, 2401-2406.	4.4	17
180	Unusual dynamics of killing of cultured lewis lung cells by the DNA-intercalating antitumour agentN-[2-(dimethylamino)ethyl]acridine-4-carboxamide. Cancer Chemotherapy and Pharmacology, 1992, 29, 475-479.	2.3	17

#	Article	IF	Citations
181	Nitric oxide: its production in host-cell-infiltrated EMT6 spheroids and its role in tumour cell killing by flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemotherapy and Pharmacology, 1992, 31, 151-155.	2.3	17
182	Potential antitumor agents. 62. Structure-activity relationships for tricyclic compounds related to the colon tumor active drug 9-oxo-9H-xanthene-4-acetic acid. Journal of Medicinal Chemistry, 1991, 34, 491-496.	6.4	39
183	Induction of natural killer activity by Xanthenone analogues of flavone acetic acid: Relation with antitumour activity. European Journal of Cancer & Clinical Oncology, 1991, 27, 79-83.	0.7	14
184	Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: Evidence for a vascular mechanism. European Journal of Cancer & Clinical Oncology, 1991, 27, 482-487.	0.7	149
185	Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer. European Journal of Cancer & Clinical Oncology, 1991, 27, 1617-1620.	0.7	22
186	Potential antitumor agents. 63. Structure-activity relationships for side-chain analogs of the colon 38 active agent 9-oxo-9H-xanthene-4-acetic acid. Journal of Medicinal Chemistry, 1991, 34, 2864-2870.	6.4	61
187	DNA-directed alkylating agents. 4. 4-Anilinoquinoline-based minor groove directed aniline mustards. Journal of Medicinal Chemistry, 1991, 34, 1552-1560.	6.4	26
188	In vitro methods for screening agents with an indirect mechanism of antitumour activity: Xanthenone analogues of flavone acetic acid. European Journal of Cancer & Clinical Oncology, 1991, 27, 1684-1689.	0.7	13
189	Stimulation of bacterial mutagenicity by inhibitors of mammalian cell multidrug resistance. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1991, 264, 231-234.	1.1	2
190	Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. Journal of Medicinal Chemistry, 1991, 34, 217-222.	6.4	187
191	Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice. Cancer Chemotherapy and Pharmacology, 1991, 28, 409-413.	2.3	31
192	Haematological effects in mice of the antitumour agents xanthenone-4-acetic acid, 5,6-methyl-xanthenone-4-acetic acid and flavone acetic acid. Cancer Chemotherapy and Pharmacology, 1991, 28, 414-419.	2.3	8
193	Design of NDA Intercalators To Overcome Topoisomerase II-Mediated Multidurg Resistance. Journal of the National Cancer Institute, 1990, 82, 398-402.	6.3	57
194	DNA-directed alkylating agents. 3. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the length of the linker chain. Journal of Medicinal Chemistry, 1990, 33, 3014-3019.	6.4	47
195	DNA-directed alkylating agents. 2. Synthesis and biological activity of platinum complexes linked to 9-anilinoacridine. Journal of Medicinal Chemistry, 1990, 33, 3008-3014.	6.4	57
196	Genetic toxicology of tricyclic carboxamides, a new class of DNA binding antitumour agent. European Journal of Cancer & Clinical Oncology, 1990, 26, 709-714.	0.7	10
197	Potentiation by phenylbisbenzimidazoles of cytotoxicity of anticancer drugs directed against topoisomerase II. European Journal of Cancer & Clinical Oncology, 1990, 26, 586-589.	0.7	20
198	Protection by inhibitors of multidrug resistance against mitochondrial mutagenesis in Saccharomyces cerevisiae. European Journal of Cancer & Clinical Oncology, 1990, 26, 55-60.	0.7	11

#	Article	IF	Citations
199	DNA-directed alkylating agents. 1. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the reactivity of the mustard. Journal of Medicinal Chemistry, 1990, 33, 1177-1186.	6.4	83
200	Potential antitumor agents. 59. Structure-activity relationships for 2-phenylbenzimidazole-4-carboxamides, a new class of minimal DNA-intercalating agents which may not act via topoisomerase II. Journal of Medicinal Chemistry, 1990, 33, 814-819.	6.4	284
201	Potential antitumor agents. 60. Relationships between structure and in vivo colon 38 activity for 5-substituted 9-oxoxanthene-4-acetic acids. Journal of Medicinal Chemistry, 1990, 33, 1375-1379.	6.4	42
202	Comparison of the cytotoxicity of amsacrine and its analogue CI-921 against cultured human and mouse bone marrow tumour cells. European Journal of Cancer & Clinical Oncology, 1990, 26, 49-54.	0.7	7
203	Blood Flow Failure as a Major Determinant in the Antitumor Action of Flavone Acetic Acid. Journal of the National Cancer Institute, 1989, 81, 1005-1013.	6.3	141
204	Effect of flavone acetic acid (NSC 347 512) on splenic cytotoxic effector cells and their role in tumour necrosis. European Journal of Cancer & Clinical Oncology, 1989, 25, 821-828.	0.7	22
205	Localization of a nonintercalative DNA binding antitumour drug in mitochondria: Relationship to multidrug resistance. European Journal of Cancer & Clinical Oncology, 1989, 25, 1287-1293.	0.7	9
206	Reduction of cytotoxic effector cell activity in colon 38 tumours following treatment with flavone acetic acid. European Journal of Cancer & Clinical Oncology, 1989, 25, 1061-1065.	0.7	9
207	Selectivity of N-[2-(Dimethylamino)ethyl]acridine-4-carâ˜amide towards Lewis lung carcinoma and human tumour cell lines in vitro. European Journal of Cancer & Clinical Oncology, 1989, 25, 271-277.	0.7	37
208	Hyporesponsiveness of macrophages from (endotoxin-resistant) mice to the antitumour agent flavone acetic acid (NSC 347512). European Journal of Cancer & Clinical Oncology, 1989, 25, 1513-1515.	0.7	10
209	Mutagenicity profiles of newer amsacrine analogues with activity against solid tumours: Comparison of microbial and mammalian systems. European Journal of Cancer & Clinical Oncology, 1989, 25, 255-261.	0.7	14
210	Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor Î± on Colon 38 tumours in mice. European Journal of Cancer & Clinical Oncology, 1989, 25, 263-269.	0.7	59
211	Potential antitumor agents. 57. 2-Phenylquinoline-8-carboxamides as minimal DNA-intercalating antitumor agents with in vivo solid tumor activity. Journal of Medicinal Chemistry, 1989, 32, 396-401.	6.4	143
212	Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo. Journal of Medicinal Chemistry, 1989, 32, 793-799.	6.4	118
213	Chemoprotection by 9-aminoacridine derivatives against the cytotoxicity of topoisomerase II-directed drugs. European Journal of Cancer & Clinical Oncology, 1989, 25, 1695-1701.	0.7	25
214	Verapamil as a co-mutagen in the Salmonella/mammalian microsome mutagenicity test. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1988, 209, 57-62.	1.1	32
215	The relationship between lipophilic-hydrophilic balance, uptake and anti-bacteriophage lambda activity of experimental anti-tumour bisquaternary salts. Chemico-Biological Interactions, 1988, 65, 85-95.	4.0	2
216	Potential antitumor agents. 55. 6-Phenylphenanthridine-4-carboxamides: a new class of DNA-intercalating antitumor agents. Journal of Medicinal Chemistry, 1988, 31, 774-779.	6.4	55

#	Article	IF	Citations
217	Comparison of the mutagenicity of amsacrine with that of a new clinical analogue, CI-921. Mutation Research - Genetic Toxicology Testing and Biomonitoring of Environmental Or Occupational Exposure, 1988, 204, 207-217.	1.2	16
218	Potential antitumor agents. 54. Chromophore requirements for in vivo antitumor activity among the general class of linear tricyclic carboxamides. Journal of Medicinal Chemistry, 1988, 31, 707-712.	6.4	102
219	Potential antitumor agents. 56. Minimal DNA-intercalating ligands as antitumor drugs: phenylquinoline-8-carboxamides. Journal of Medicinal Chemistry, 1988, 31, 1048-1052.	6.4	54
220	Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II. European Journal of Cancer & Clinical Oncology, 1988, 24, 1783-1790.	0.7	57
221	Enhancement of in vitro cytotoxicity of mouse peritoneal exudate cells by flavone acetic acid (NSC) Tj ETQq1 1 0.784314 rgBT /Overlock	0.7	44
222	Effects of CI-921, an analogue of amsacrine, on advanced Lewis lung tumours in mice: Relevance to clinical trials. European Journal of Cancer & Clinical Oncology, 1988, 24, 211-218.	0.7	4
223	Relationship between the structure of analogues of amsacrine and their degree of cross-resistance to adriamycin-resistant P388 leukaemia cells. European Journal of Cancer & Clinical Oncology, 1988, 24, 205-210.	0.7	6
224	Effect of Flavone Acetic Acid on Lewis Lung Carcinoma: Evidence for an Indirect Effect1. Journal of the National Cancer Institute, 1988, 80, 241-245.	6.3	72
225	Redox chemistry of the 9-anilinoacridine class of antitumor agents. Journal of Medicinal Chemistry, 1987, 30, 473-480.	6.4	32
226	Induction of natural killer cell activity by the antitumour compound flavone acetic acid (NSC 347 512). European Journal of Cancer & Clinical Oncology, 1987, 23, 1047-1050.	0.7	82
227	Potential antitumor agents. 49. 5-Substituted derivatives of N-[2-(dimethylamino)ethyl]-9-aminoacridine-4-carboxamide with in vivo solid-tumor activity. Journal of Medicinal Chemistry, 1987, 30, 658-663.	6.4	62
228	Potential antitumor agents. 48. 3'-Dimethylamino derivatives of amsacrine: redox chemistry and in vivo solid tumor activity. Journal of Medicinal Chemistry, 1987, 30, 652-658.	6.4	12
229	Potential antitumor agents. 51. Synthesis and antitumor activity of substituted phenazine-1-carboxamides. Journal of Medicinal Chemistry, 1987, 30, 843-851.	6.4	126
230	Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours. European Journal of Cancer & Clinical Oncology, 1987, 23, 1209-1211.	0.7	93
231	Comparison of in vivo and in vitro drug sensitivities of Lewis lung carcinoma and P388 leukaemia to analogues of Amsacrine. European Journal of Cancer & Clinical Oncology, 1987, 23, 607-613.	0.7	9
232	Potential antitumor agents. 52. Carbamate analogs of amsacrine with in vivo activity against multidrug-resistant P388 leukemia. Journal of Medicinal Chemistry, 1987, 30, 1576-1581.	6.4	15
233	Electron donor properties of the antitumour drug amsacrine as studied by fluorescence quenching of DNA-bound ethidium. Chemico-Biological Interactions, 1987, 62, 45-58.	4.0	22
234	Verapamil modulates mutagenicity of antitumour acridines in bacteria and yeast. Biochemical Pharmacology, 1986, 35, 4581-4584.	4.4	18

#	Article	IF	Citations
235	Potential antitumor agents. 47. 3'-Methylamino analogs of amsacrine with in vivo solid tumor activity. Journal of Medicinal Chemistry, 1986, 29, 1769-1776.	6.4	19
236	Potential antitumor agents. 45. Synthesis, DNA-binding interaction, and biological activity of triacridine derivatives. Journal of Medicinal Chemistry, 1986, 29, 69-74.	6.4	23
237	Potential antitumor agents. 46. Structure-activity relationships for acridine monosubstituted derivatives of the antitumor agent N-[2-(dimethylamino)ethyl]-9-aminoacridine-4-carboxamide. Journal of Medicinal Chemistry, 1986, 29, 472-477.	6.4	83
238	Comparison of in Vitro activity of cytotoxic drugs towards human carcinoma and leukaemia cell lines. European Journal of Cancer & Clinical Oncology, 1986, 22, 655-662.	0.7	72
239	Inverse correlation between bacterial frameshift mutagenicity and yeast mitochondrial effects of antitumour anilinoacridines. Chemico-Biological Interactions, 1985, 56, 145-155.	4.0	13
240	Potential antitumor agents. 44. Synthesis and antitumor activity of new classes of diacridines: importance of linker chain rigidity for DNA binding kinetics and biological activity. Journal of Medicinal Chemistry, 1985, 28, 1568-1574.	6.4	95
241	9-anilinoacridines: Novel compounds active against herpes simplex virus. Chemico-Biological Interactions, 1985, 54, 377-382.	4.0	6
242	Schedule dependence of activity of the amsacrine analogue CI-921 towards P388 leukaemia and Lewis lung carcinoma. European Journal of Cancer & Clinical Oncology, 1985, 21, 1337-1341.	0.7	2
243	A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. Analytical Biochemistry, 1984, 139, 272-277.	2.4	192
244	Potential antitumor agents. 40. Orally active 4,5-disubstituted derivatives of amsacrine. Journal of Medicinal Chemistry, 1984, 27, 363-367.	6.4	27
245	Potential antitumor agents. 42. Structure-activity relationships for acridine-substituted dimethyl phosphoramidate derivatives of 9-anilinoacridine. Journal of Medicinal Chemistry, 1984, 27, 1053-1056.	6.4	9
246	The use of human cancer cell lines as a primary screening system for antineoplastic compounds. European Journal of Cancer & Clinical Oncology, 1984, 20, 947-954.	0.7	38
247	Differential growth inhibition of cultured mammalian cells: Comparison of clinical antitumour agents and amsacrine derivatives. European Journal of Cancer & Clinical Oncology, 1984, 20, 383-389.	0.7	10
248	Potential antitumor agents. 41. Analogs of amsacrine with electron-donor substituents in the anilino ring. Journal of Medicinal Chemistry, 1984, 27, 367-372.	6.4	12
249	Potential antitumor agents. Part 43. Synthesis and biological activity of dibasic 9-aminoacridine-4-carboxamides, a new class of antitumor agent. Journal of Medicinal Chemistry, 1984, 27, 1481-1485.	6.4	109
250	Comparative studies of mutagenic, DNA binding and antileukaemic properties of 9-anilinoacridine derivatives and related compounds. Chemico-Biological Interactions, 1983, 44, 53-62.	4.0	25
251	Induction of petite mutants in yeast by non-intercalative DNA-binding antitumour agents. European Journal of Cancer & Clinical Oncology, 1983, 19, 1575-1583.	0.7	18
252	Potential antitumor agents. 39. Anilino ring geometry of amsacrine and derivatives: relationship to DNA binding and antitumor activity. Journal of Medicinal Chemistry, 1983, 26, 1625-1630.	6.4	29

#	Article	IF	Citations
253	Divergent activity of derivatives of amsacrine (m-AMSA) towards Lewis lung carcinoma and P388 leukaemia in mice. European Journal of Cancer & Clinical Oncology, 1983, 19, 1607-1613.	0.7	22
254	Potential antitumor agents. Part 38. 3-Substituted 5-carboxamido derivatives of amsacrine. Journal of Medicinal Chemistry, 1983, 26, 1619-1625.	6.4	22
255	A comparison of the requirements for antitumour activity and antibacteriophage lambda activity for a series of non-intercalative DNA-binding agents. European Journal of Cancer & Clinical Oncology, 1982, 18, 271-279.	0.7	7
256	Potential antitumor agents. 37. Organophosphorus derivatives of 9-anilinoacridine. Journal of Medicinal Chemistry, 1982, 25, 1231-1235.	6.4	16
257	Potential antitumor agents. 34. Quantitative relationships between DNA binding and molecular structure for 9-anilinoacridines substituted in the anilino ring. Journal of Medicinal Chemistry, 1981, 24, 170-177.	6.4	188
258	Mutagenic potency and drug structure in some experimental anti-cancer drugs. Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology, 1980, 74, 420.	0.4	0
259	Potential antitumor agents. 29. Quantitative structure-activity relationships for the antileukemic bisquaternary ammonium heterocycles. Journal of Medicinal Chemistry, 1979, 22, 134-150.	6.4	142
260	Potential antitumor agents. 28. Deoxyribonucleic acid polyintercalating agents. Journal of Medicinal Chemistry, 1978, 21, 658-668.	6.4	200
261	The interaction of ethidium with synthetic double-stranded polynucleotides at low ionic strength. Nucleic Acids Research, 1978, 5, 161-171.	14.5	151
262	Thiolytic cleavage of the anti-tumour compound 4â€²-(9-acridinylamino)-methanesulphon-m-anisidine (m-AMSA, NSC 156 303) in blood. Chemico-Biological Interactions, 1977, 18, 163-178.	4.0	32
263	The immunological status of mice during the generation of cyclophosphamide-induced tolerance. Cellular Immunology, 1976, 25, 217-227.	3.0	9